FDA's AI rulebook for generative devices nears its first deadline, with no answer yet on who counts as a device

A discussion paper from the FDA's Digital Health Center of Excellence proposes how to grade generative AI tools by risk, but leaves unresolved whether software that turns caregiver logs into clinician-ready summaries is a regulated medical device at all. Public comment closes October 19.

The Food and Drug Administration's Digital Health Center of Excellence, part of the Center for Devices and Radiological Health, published a discussion paper on August 18, 2026 titled "Considerations for the Regulation of Generative AI-Enabled Medical Devices," opening a public comment period under docket FDA-2026-N-7874 that closes October 19, 2026, according to the agency's own notice and the docket's posting on Regulations.gov. The paper proposes a two-axis framework for judging risk, one axis measuring how directive a tool's output is (from purely informational to fully autonomous action) and the other measuring the harm of a wrong output, with a premarket evaluation model the agency compares to physician credentialing, combining benchmark testing with clinical confirmation, as reported by Axios and MedTech Dive coverage of the release.

The paper matters to dementia care specifically because software that condenses caregiver logs, daily behavior notes, or medication diaries into a physician-ready brief would likely sit, if it is regulated at all, in the lowest-risk "informational, non-directive" category the paper describes, alongside examples like a software-generated risk score. But the FDA states explicitly, as legal analyses of the paper by the law firm Maynard Nexsen and the device consultancy Innolitics both note, that the discussion paper "does not address whether the approaches discussed fall within FDA's existing legal authorities," meaning it does not resolve the threshold question of whether a given summarization tool meets the statutory definition of a medical device in the first place. That gap is exactly what determines whether a caregiver-log summarizer must ever go through FDA review, or can market its output as a clinical aid without agency oversight.

FDA officials have framed the document as deliberately preliminary. Michelle Tarver, director of the Center for Devices and Radiological Health, said the agency is "launching a transparent process to inform the development of an approach that safeguards patients and consumers," according to the FDA's own announcement reported by The ASCO Post. The agency has authorized more than 1,600 AI-enabled medical devices as of September 2026, per FDA's own device list, but the agency has said most of those do not use generative AI, and no generative-AI-enabled device has yet been cleared or approved under any pathway, according to MedTech Dive's reporting on the discussion paper.

The counterpoint, raised by commenters already filed to the docket and by policy analysts who reviewed the paper, is that it is not guidance and creates no binding rule: it proposes no policy change, sets no evidence standard a manufacturer must meet, and will not itself determine what any product can claim. Whatever the agency does next, whether it issues draft guidance, revises the framework, or declines to act, will come only after the comment window closes and the agency reviews what stakeholders submitted, a process FDA's digital health director Rick Abramson has told STAT will eventually produce formal guidance documents, without giving a date.

For families and clinicians using or considering a log-to-summary tool today, nothing changes this week: no claim any such product makes has been vetted against this framework, because the framework itself does not yet exist as policy. The practical marker to watch is whether FDA, after October 19, narrows or clarifies which documentation and summarization software counts as a device, since that decision, not this discussion paper, will be what eventually governs what such tools may say about what they do.